{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:34:22Z","timestamp":1779165262502,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Adjuvant gemcitabine for pancreatic cancer has limited efficacy in the clinical setting. Impaired drug metabolism is associated with treatment resistance. We aimed to evaluate the chemosensitising effect of interferon-beta (IFN-\u03b2)\n                      <jats:italic>.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>BxPC-3, CFPAC-1, and Panc-1 cells were pre-treated with IFN-\u03b2 followed by gemcitabine monotherapy. The effect on cell growth, colony formation, and cell cycle was determined. RT-qPCR was used to measure gene expression. BxPC-3 cells were used in a heterotopic subcutaneous mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IFN-\u03b2 increased sensitivity to gemcitabine (4-, 7.7-, and 1.7-fold EC\n                      <jats:sub>50<\/jats:sub>\n                      decrease in BxPC-3, CFPAC-1, and Panc-1, respectively; all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Findings were confirmed when assessing colony formation. The percentage of cells in the S-phase was significantly increased after IFN-\u03b2 treatment only in BxPC-3 and CFPAC-1 by 12 and 7%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05, respectively). Thereby, IFN-\u03b2 upregulated expression of the drug transporters\n                      <jats:italic>SLC28A1<\/jats:italic>\n                      in BxPC-3 (252%) and\n                      <jats:italic>SLC28A3<\/jats:italic>\n                      in BxPC-3 (127%) and CFPAC-1 (223%) (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In vivo, combination therapy reduced tumor volume with 45% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01). Both ex vivo and in vivo data demonstrate a significant reduction in the number of proliferating cells, whereas apoptosis was increased.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For the first time, we validated the chemosensitising effects of IFN-\u03b2 when combined with gemcitabine in vitro, ex vivo, and in vivo. This was driven by cell cycle modulation and associated with an upregulation of genes involving intracellular uptake of gemcitabine. The use of IFN-\u03b2 in combination with gemcitabine seems promising in patients with pancreatic cancer and needs to be further explored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07420-0","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T08:03:02Z","timestamp":1600848182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Amber","family":"Blaauboer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Booy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"van Koetsveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bas","family":"Karels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadime","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"van Zwienen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casper H. J.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo J.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"1","key":"7420_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"7420_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0003-3944(00)00251-0","volume":"125","author":"J Baulieux","year":"2000","unstructured":"Baulieux J, Delpero JR. [surgical treatment of pancreatic cancer: curative resections] Traitement chirurgical du cancer du pancreas: les exereses a visee curative. Ann Chir. 2000;125(7):609\u201317.","journal-title":"Ann Chir"},{"issue":"14","key":"7420_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Jama. 2013;310(14):1473\u201381.","journal-title":"Jama."},{"issue":"25","key":"7420_CR4","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic Cancer. N Engl J Med. 2018;379(25):2395\u2013406.","journal-title":"N Engl J Med"},{"issue":"5","key":"7420_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12325-016-0327-4","volume":"33","author":"M Tehfe","year":"2016","unstructured":"Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, et al. Nab-paclitaxel plus gemcitabine versus gemcitabine in patients with metastatic pancreatic adenocarcinoma: Canadian subgroup analysis of the phase 3 MPACT trial. Adv Ther. 2016;33(5):747\u201359.","journal-title":"Adv Ther"},{"issue":"11","key":"7420_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4251\/wjgo.v3.i11.153","volume":"3","author":"IA Voutsadakis","year":"2011","unstructured":"Voutsadakis IA. Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol. 2011;3(11):153\u201364.","journal-title":"World J Gastrointest Oncol"},{"key":"7420_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"CL de Sousa","year":"2014","unstructured":"de Sousa CL, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8\u201316.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"7420_CR8","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/1078-0432.CCR-08-2080","volume":"15","author":"R Marechal","year":"2009","unstructured":"Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009;15(8):2913\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"7420_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.bjc.6603559","volume":"96","author":"Y Nakano","year":"2007","unstructured":"Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007;96(3):457\u201363.","journal-title":"Br J Cancer"},{"key":"7420_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1756-9966-28-83","volume":"28","author":"R Ashida","year":"2009","unstructured":"Ashida R, Nakata B, Shigekawa M, Mizuno N, Sawaki A, Hirakawa K, et al. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. J Exp Clin Cancer Res. 2009;28:83.","journal-title":"J Exp Clin Cancer Res"},{"issue":"29","key":"7420_CR11","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1038\/onc.2013.357","volume":"33","author":"N Weizman","year":"2014","unstructured":"Weizman N, Krelin Y, Shabtay-Orbach A, Amit M, Binenbaum Y, Wong RJ, et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene. 2014;33(29):3812\u20139.","journal-title":"Oncogene."},{"issue":"5","key":"7420_CR12","first-page":"1237","volume":"38","author":"Y Tomimaru","year":"2011","unstructured":"Tomimaru Y, Eguchi H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, et al. Synergistic antitumor effect of interferon-ss with gemcitabine in interferon-alpha-non-responsive pancreatic cancer cells. Int J Oncol. 2011;38(5):1237\u201343.","journal-title":"Int J Oncol"},{"issue":"13","key":"7420_CR13","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.ejca.2011.03.009","volume":"47","author":"MJ Morak","year":"2011","unstructured":"Morak MJ, van Koetsveld PM, Kanaar R, Hofland LJ, van Eijck CH. Type I interferons as radiosensitisers for pancreatic cancer. Eur J Cancer. 2011;47(13):1938\u201345.","journal-title":"Eur J Cancer"},{"issue":"9","key":"7420_CR14","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3109\/09553002.2010.481321","volume":"86","author":"E Jost","year":"2010","unstructured":"Jost E, Roos WP, Kaina B, Schmidberger H. Response of pancreatic cancer cells treated with interferon-alpha or beta and co-exposed to ionising radiation. Int J Radiat Biol. 2010;86(9):732\u201341.","journal-title":"Int J Radiat Biol"},{"issue":"1\u20134","key":"7420_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/08830189809084487","volume":"17","author":"E De Maeyer","year":"1998","unstructured":"De Maeyer E, De Maeyer-Guignard J. Type I interferons. Int Rev Immunol. 1998;17(1\u20134):53\u201373.","journal-title":"Int Rev Immunol"},{"issue":"3","key":"7420_CR16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/jcmm.12200","volume":"18","author":"S Booy","year":"2014","unstructured":"Booy S, van Eijck CH, Dogan F, van Koetsveld PM, Hofland LJ. Influence of type-I interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells. J Cell Mol Med. 2014;18(3):492\u2013502.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"7420_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/01.sla.0000261460.07110.f2","volume":"246","author":"G Vitale","year":"2007","unstructured":"Vitale G, van Eijck CH, van Koetsveld Ing PM, Erdmann JI, Speel EJ, van der Wansem IK, et al. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg. 2007;246(2):259\u201368.","journal-title":"Ann Surg"},{"issue":"11","key":"7420_CR18","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1210\/jc.2006-0620","volume":"91","author":"PM van Koetsveld","year":"2006","unstructured":"van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, et al. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab. 2006;91(11):4537\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2\u20133","key":"7420_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12672-019-00361-6","volume":"10","author":"AD Herrera-Martinez","year":"2019","unstructured":"Herrera-Martinez AD, Feelders RA, de Herder WW, Castano JP, Galvez Moreno MA, Dogan F, et al. Effects of ketoconazole on ACTH-producing and non-ACTH-producing neuroendocrine tumor cells. Horm Cancer. 2019;10(2\u20133):107\u201319.","journal-title":"Horm Cancer"},{"issue":"7","key":"7420_CR20","doi-asserted-by":"publisher","first-page":"RESEARCH0034","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.","journal-title":"Genome Biol"},{"issue":"1","key":"7420_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/MPA.0000000000000202","volume":"44","author":"S Booy","year":"2015","unstructured":"Booy S, Hofland LJ, Waaijers AM, Croze E, van Koetsveld PM, de Vogel L, et al. Type I interferon receptor expression in human pancreatic and Periampullary Cancer tissue. Pancreas. 2015;44(1):99\u2013105.","journal-title":"Pancreas."},{"issue":"10","key":"7420_CR22","doi-asserted-by":"publisher","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","volume":"7","author":"AE Carpenter","year":"2006","unstructured":"Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7(10):R100.","journal-title":"Genome Biol"},{"issue":"18","key":"7420_CR23","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1038\/sj.onc.1202609","volume":"18","author":"O Sangfelt","year":"1999","unstructured":"Sangfelt O, Erickson S, Castro J, Heiden T, Gustafsson A, Einhorn S, et al. Molecular mechanisms underlying interferon-alpha-induced G0\/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene. 1999;18(18):2798\u2013810.","journal-title":"Oncogene."},{"issue":"Database issue","key":"7420_CR24","doi-asserted-by":"publisher","first-page":"D852","DOI":"10.1093\/nar\/gkn732","volume":"37","author":"SA Samarajiwa","year":"2009","unstructured":"Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res. 2009;37(Database issue):D852\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"7420_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.tim.2014.12.003","volume":"23","author":"O Haller","year":"2015","unstructured":"Haller O, Staeheli P, Schwemmle M, Kochs G. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol. 2015;23(3):154\u201363.","journal-title":"Trends Microbiol"},{"issue":"31","key":"7420_CR26","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1038\/sj.onc.1210237","volume":"26","author":"F Demichelis","year":"2007","unstructured":"Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596\u20139.","journal-title":"Oncogene."},{"issue":"22","key":"7420_CR27","doi-asserted-by":"publisher","first-page":"15206","DOI":"10.1074\/jbc.M806324200","volume":"284","author":"JF Mushinski","year":"2009","unstructured":"Mushinski JF, Nguyen P, Stevens LM, Khanna C, Lee S, Chung EJ, et al. Inhibition of tumor cell motility by the interferon-inducible GTPase MxA. J Biol Chem. 2009;284(22):15206\u201314.","journal-title":"J Biol Chem"},{"issue":"3","key":"7420_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/pros.22912","volume":"75","author":"SG Brown","year":"2015","unstructured":"Brown SG, Knowell AE, Hunt A, Patel D, Bhosle S, Chaudhary J. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis. Prostate. 2015;75(3):266\u201379.","journal-title":"Prostate."},{"issue":"11","key":"7420_CR29","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301\u20139.","journal-title":"Nat Med"},{"issue":"11","key":"7420_CR30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3748\/wjg.15.1359","volume":"15","author":"MA van Geer","year":"2009","unstructured":"van Geer MA, Kuhlmann KF, Bakker CT, ten Kate FJ, Oude Elferink RP, Bosma PJ. Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices. World J Gastroenterol. 2009;15(11):1359\u201366.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"7420_CR31","doi-asserted-by":"publisher","first-page":"e76229","DOI":"10.1371\/journal.pone.0076229","volume":"8","author":"V Rebours","year":"2013","unstructured":"Rebours V, Albuquerque M, Sauvanet A, Ruszniewski P, Levy P, Paradis V, et al. Hypoxia pathways and cellular stress activate pancreatic stellate cells: development of an organotypic culture model of thick slices of normal human pancreas. PLoS One. 2013;8(9):e76229.","journal-title":"PLoS One"},{"issue":"9","key":"7420_CR32","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","volume":"17","author":"NV Rajeshkumar","year":"2011","unstructured":"Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011;17(9):2799\u2013806.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7420_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4161\/cbt.10.1.12169","volume":"10","author":"N Awasthi","year":"2010","unstructured":"Awasthi N, Schwarz MA, Schwarz RE. Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer. Cancer Biol Ther. 2010;10(1):99\u2013107.","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"7420_CR34","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1089\/10799900050163226","volume":"20","author":"PA Buchwalder","year":"2000","unstructured":"Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interf Cytokine Res. 2000;20(10):857\u201366.","journal-title":"J Interf Cytokine Res"},{"issue":"1","key":"7420_CR35","first-page":"42","volume":"1845","author":"A Dicitore","year":"2014","unstructured":"Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D, et al. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-gamma (PPAR-gamma): at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta. 2014;1845(1):42\u201352.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"7420_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.biotechadv.2011.08.001","volume":"30","author":"G Vitale","year":"2012","unstructured":"Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, et al. The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-beta treated pancreatic cancer cells. Biotechnol Adv. 2012;30(1):169\u201384.","journal-title":"Biotechnol Adv"},{"issue":"3","key":"7420_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16(3):131\u201344.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"7420_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","volume":"4","author":"JR Quesada","year":"1986","unstructured":"Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986;4(2):234\u201343.","journal-title":"J Clin Oncol"},{"issue":"6","key":"7420_CR39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1089\/jir.2007.0183","volume":"27","author":"S Ogasawara","year":"2007","unstructured":"Ogasawara S, Yano H, Momosaki S, Akiba J, Nishida N, Kojiro S, et al. Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo. J Interf Cytokine Res. 2007;27(6):507\u201316.","journal-title":"J Interf Cytokine Res"},{"issue":"52","key":"7420_CR40","doi-asserted-by":"publisher","first-page":"13792","DOI":"10.1073\/pnas.1713728114","volume":"114","author":"MR Doherty","year":"2017","unstructured":"Doherty MR, Cheon H, Junk DJ, Vinayak S, Varadan V, Telli ML, et al. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2017;114(52):13792\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"7420_CR41","doi-asserted-by":"publisher","first-page":"e72709","DOI":"10.1371\/journal.pone.0072709","volume":"8","author":"Q Li","year":"2013","unstructured":"Li Q, Kawamura K, Yang S, Okamoto S, Kobayashi H, Tada Y, et al. Interferon-\u03b2 produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells. PLoS One. 2013;8(8):e72709.","journal-title":"PLoS One"},{"key":"7420_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fphar.2015.00013","volume":"6","author":"M Pastor-Anglada","year":"2015","unstructured":"Pastor-Anglada M, P\u00e9rez-Torras S. Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front Pharmacol. 2015;6:13.","journal-title":"Front Pharmacol"},{"issue":"1\u20132","key":"7420_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.drup.2012.01.009","volume":"15","author":"JA Sprowl","year":"2012","unstructured":"Sprowl JA, Mikkelsen TS, Giovinazzo H, Sparreboom A. Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat. 2012;15(1\u20132):5\u201320.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"7420_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","volume":"18","author":"EC Borden","year":"2019","unstructured":"Borden EC. Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019;18(3):219\u201334.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"7420_CR45","first-page":"1059","volume":"297","author":"RB Pepinsky","year":"2001","unstructured":"Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther. 2001;297(3):1059\u201366.","journal-title":"J Pharmacol Exp Ther"},{"issue":"31","key":"7420_CR46","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","volume":"30","author":"AM Eggermont","year":"2012","unstructured":"Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"7420_CR47","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/annonc\/mdf288","volume":"13","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, et al. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol. 2002;13(11):1799\u2013805.","journal-title":"Ann Oncol"},{"issue":"1","key":"7420_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11095-004-9009-z","volume":"22","author":"DE Mager","year":"2005","unstructured":"Mager DE, Neuteboom B, Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res. 2005;22(1):58\u201361.","journal-title":"Pharm Res"},{"issue":"6","key":"7420_CR49","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1177\/0091270011407068","volume":"52","author":"X Hu","year":"2012","unstructured":"Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, et al. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol. 2012;52(6):798\u2013808.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"7420_CR50","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00262-019-02422-9","volume":"68","author":"J Burks","year":"2019","unstructured":"Burks J, Fleury A, Livingston S, Smith JP. ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression. Cancer Immunol Immunother. 2019;68(12):2029\u201339.","journal-title":"Cancer Immunol Immunother"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07420-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07420-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07420-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T19:24:17Z","timestamp":1632338657000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07420-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7420"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07420-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-39801\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-39801\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-39801\/v3","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All mouse experiments were controlled by the animal welfare committee (IvD) of the Erasmus Medical Center and approved by the national central committee of animal experiments (CCD) under the protocol number 105\u201312-52, in accordance with the Dutch Act on Animal Experimentation and EU Directive 2010\/63\/EU. This study was performed in accordance with the Declaration of Helsinki.The maximum tumor size that was permitted by the ethic committee was 2000mm<sup>3<\/sup>. This size was not exceeded during the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"913"}}